Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T.

Brain. 2011 May;134(Pt 5):1493-505. doi: 10.1093/brain/awr031.

2.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
3.

Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.

Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, Katsuse O, Uchikado H, Aoki N, Kosaka K, Arai H, Sato K.

Neurosci Lett. 2010 Dec 3;486(1):19-23. doi: 10.1016/j.neulet.2010.09.036.

PMID:
20851165
4.

Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.

Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ, Clarimón J, Lleó A.

J Neuropathol Exp Neurol. 2013 Dec;72(12):1203-12. doi: 10.1097/NEN.0000000000000018.

PMID:
24226269
5.

Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias.

Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, Hortobágyi T, Francis PT.

Brain Pathol. 2015 Jul;25(4):401-8. doi: 10.1111/bpa.12182.

PMID:
25103200
6.

The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia.

Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, Lees AJ, Revesz T.

Neurodegener Dis. 2014;13(2-3):154-6. doi: 10.1159/000354670.

7.

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS.

Arch Neurol. 2012 Oct;69(10):1326-31.

8.

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

Jellinger KA, Attems J.

Acta Neuropathol. 2008 Apr;115(4):427-36. doi: 10.1007/s00401-008-0347-5.

PMID:
18273624
9.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670.

PMID:
21469206
10.

Neuropathologic substrates of Parkinson disease dementia.

Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ.

Ann Neurol. 2012 Oct;72(4):587-98. doi: 10.1002/ana.23659.

11.

A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.

Jellinger KA.

Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Review.

12.

Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.

Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J.

Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3.

PMID:
25758940
13.

Correlations between cortical and subcortical tau pathology.

Attems J, Thomas A, Jellinger K.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):582-90. doi: 10.1111/j.1365-2990.2011.01244.x.

PMID:
22115520
14.

Limbic neuropathology in idiopathic Parkinson's disease with concomitant dementia.

Bertrand E, Lechowicz W, Szpak GM, Lewandowska E, Dymecki J, Wierzba-Bobrowicz T.

Folia Neuropathol. 2004;42(3):141-50.

PMID:
15535032
15.

Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease.

Halliday GM, Song YJ, Harding AJ.

J Neural Transm (Vienna). 2011 May;118(5):713-9. doi: 10.1007/s00702-011-0641-6.

PMID:
21479514
16.

Morphological substrates of mental dysfunction in Lewy body disease: an update.

Jellinger KA.

J Neural Transm Suppl. 2000;59:185-212.

PMID:
10961431
17.

Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.

Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW.

Neuropathol Appl Neurobiol. 2003 Oct;29(5):503-10.

PMID:
14507342
18.

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.

Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM.

J Neurosci. 2010 May 26;30(21):7281-9. doi: 10.1523/JNEUROSCI.0490-10.2010.

19.

ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies.

Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM.

Acta Neuropathol Commun. 2013 May 9;1:11. doi: 10.1186/2051-5960-1-11.

20.

Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.

Dijkstra AA, Voorn P, Berendse HW, Groenewegen HJ; Netherlands Brain Bank., Rozemuller AJ, van de Berg WD.

Mov Disord. 2014 Sep;29(10):1244-51. doi: 10.1002/mds.25952.

PMID:
24996051
Items per page

Supplemental Content

Support Center